Entrepreneur with GSK roots targets lung transplant survival rates with UNC technology

In a tiny lab in Chapel Hill, a 3-year-old startup with UNC-Chapel Hill technology is trying to help lung transplant patients defy the odds. Each year, about 2,000 people receive lung transplants. And the five-year survival rate for those patients is just over half, according to the National Heart, Lung and Blood Institute. Renovion CEO Dan Copeland says a product being developed in Chapel Hill could fight that statistic. “We want t o be the first drug to be FDA approved for lung transplant patients,”…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news